

Tozinameran

S

Myopericarditis: 8 case reports

A study involving patients presented to emergency department at United States with myopericarditis between 1 January 2021 and 20 May 2021 described eight male patients, aged 16–24 years, who developed myopericarditis following administration of tozinameran for immunisation against COVID-19 [*routes, dosages and time to reaction onsets not stated*].

Eight male patients received two doses of tozinameran [Pfizer-BioNTech BNT162b2 vaccine] for immunisation against COVID-19. After 1–7 days from the second dose of tozinameran, all eight patients presented to the hospital with chief complaint of chest pain. Elevated levels of troponin were noted in all the patients and seven of these patients had abnormal ECG changes. Echocardiogram was unremarkable in all patients except for one patient, which showed mild basal inferoseptal hypokinesis. Five patients underwent cardiac MRI, with common findings of oedema, fibrosis, hyperemia or delayed enhancement meeting, suggestive for diagnosis of myopericarditis. All the patients were diagnosed with myopericarditis, which was attributed to tozinameran.

The patients were treated with unspecified steroids, IV immune-globulin, aspirin or unspecified NSAIDs. Cardiac catheterisation was performed in one patient. All the patients showed improvement in symptoms. After 1–4 days of hospital stay, the patients were discharged home on medications including unspecified steroid taper, aspirin, NSAIDs or colchicine.

Fleming-Nouri A, et al. Myopericarditis in young adults presenting to the emergency department after receiving a second COVID-19 mRNA vaccine. *Academic Emergency Medicine* 28: 802-805, No. 7, Jul 2021. Available from: URL: <http://doi.org/10.1111/acem.14307>

803629539